Inhibitory Effects of Scopoletin in Collagen-induced Human Platelet Aggregation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Platelet aggregation is essential for the formation of a hemostatic plug in the case of blood vessel damage. On the other hand, excessive platelet aggregation may cause cardiovascular disorders, such as thrombosis, atherosclerosis, and myocardial infarction. Scopoletin, which found in the root of plants in the genus Scopolia or Artemisia, has anti-coagulation and anti-malaria effects. This study examined the effects of scopoletin on human platelet aggregation induced by collagen. Scopoletin had anti-platelet effects via the down-regulation of thromboxane A2 (TXA2) production and intracellular Ca2+ mobilization ([Ca2+]i), which are aggregation-inducing molecules produced in activated platelets. On the other hand, scopoletin increased both the cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels, which are known as intracellular Ca2+-antagonists and aggregation-inhibiting molecules. In particular, scopoletin increased the potently cAMP level more than cGMP, which led to suppressed fibrinogen binding to IIb/3 in collagen-induced human platelet aggregation. In addition, scopoletin inhibited collagen-elevated adenosine triphosphate (ATP) release in a dose-dependent manner. The results suggest that aggregation amplification through granule secretion is inhibited by scopoletin. Therefore, scopoletin has potent anti-platelet effects and may have potential for the prevention of platelet-derived vascular diseases.
Abstract
Platelet aggregation is essential for the formation of a hemostatic plug in the case of blood vessel damage. On the other hand, excessive platelet aggregation may cause cardiovascular disorders, such as thrombosis, atherosclerosis, and myocardial infarction. Scopoletin, which found in the root of plants in the genus Scopolia or Artemisia, has anti-coagulation and anti-malaria effects. This study examined the effects of scopoletin on human platelet aggregation induced by collagen. Scopoletin had anti-platelet effects via the down-regulation of thromboxane A2 (TXA2) production and intracellular Ca2+ mobilization ([Ca2+]i), which are aggregation-inducing molecules produced in activated platelets. On the other hand, scopoletin increased both the cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels, which are known as intracellular Ca2+-antagonists and aggregation-inhibiting molecules. In particular, scopoletin increased the potently cAMP level more than cGMP, which led to suppressed fibrinogen binding to IIb/3 in collagen-induced human platelet aggregation. In addition, scopoletin inhibited collagen-elevated adenosine triphosphate (ATP) release in a dose-dependent manner. The results suggest that aggregation amplification through granule secretion is inhibited by scopoletin. Therefore, scopoletin has potent anti-platelet effects and may have potential for the prevention of platelet-derived vascular diseases.
참고문헌 (27)
- Schwartz SM, "Developmental mechanisms underlying pathology of arteries", Physiol Rev, 70, pp.1177~1209 (1990)[DOI]
- Cattaneo M, "In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production", Thromb Res, 62, pp.717~724 (1991)
- Nishikawa M, "Ca2+-calmodulin-dependent phosphorylation and platelet secretion", Nature, 287, pp.863~865 (1980)
- Kaibuchi K, "Phosphatidylinositol turnover in platelet activation; calcium mobilization and protein phosphorylation", Cell Calcium, 3, pp.323~335 (1982)
- Menshikov MYu, "Influence of the cGMP analog 8-PCPT-cGMP on agonist-induced increases in cytosolic ionized Ca2+ and on aggregation of human platelets", Eur J Pharmacol, 245, pp.281~284 (1993)
- Atkinson BT, "Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin", Eur J Biochem, 268, pp.5242~5248 (2001)
- Kawada T, "cGMPkinase mediates cGMP-and cAMP-induced Ca2+ desensitization of skinned rat artery", Eur J Pharmacol, 323, pp.75~82 (1997)
- Calderwood DA, "Integrins and actin filaments : reciprocal regulation of cell adhesion and signaling", J Biol Chem, 275, pp.22607~22610 (2000)[DOI]
- Smolenski A, "Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO", cGMP effects, 1998, pp.358, 134~139
- Melissa J. Towler, "Variations in key artemisinic and other metabolites throughout plant development in Artemisia annua L. for potential therapeutic use", Industrial Crops and Products, 67, pp.185~191 (2015), Elsevier BV[DOI]
- Obasi SC, "Effects of single oral doses of scopoletin and aflatoxin B1 on the clotting time, serum cholesterol and phospholipid levels of chicks", Indian J Physiol Pharmacol, 38, pp.89~94 (1994)
- 권혁우, "PI3K, Akt, p38을 포함한 인산화단백질에 대한 Cordycepin의 억제효과", 대한임상검사과학회지, 49(2), pp.99~107 (2017), 대한임상검사과학회[DOI]
- Schaeffer J, "Platelet free calcium concentrations measured with fura-2 are influenced by the transmembrane sodium gradient", Cell Calcium, 10, pp.101~113 (1989)
- Kawada N, "Regulation by cAMP of STAT1 activation in hepatic stellate cells", Biochem Biophys Res Commun, 233, pp.464~469 (1997)[DOI]
- Horstrup K, "Phosphorylation of focal adhesion vasodilatorstimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition", Eur J Biochem, 225, pp.21~27 (1994)
- Barragan P, "Resistance to thienopyridines : clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation", Catheter Cardiovasc Interv, 59, pp.295~302 (2003)[DOI]
- Berridge MJ, "Inositol phosphates and cell signalling", Nature, 341, pp.197~205 (1989)[DOI]
- Okwu AK, "Homologous desensitization of human platelet thromboxane A2", prostaglandin H2 receptors, 1992, pp.262, 238~245
- Kuo JF, "Calcium-dependent protein kinase : widespread occurrence in various tissues and phyla of the animal kingdom and comparison of effects of phospholipid, calmodulin, and trifluoperazine", Proc Natl Acad Sci USA, 77, pp.7039~7043 (1980)
- Juyi Gao, "Identification and characterization of phosphodiesterases that specifically degrade 3′3′-cyclic GMP-AMP", Cell Research, 25(5), pp.539~550 (2015), Springer Science and Business Media LLC[DOI]
- Haslam RJ, "Cyclic nucleotides and phosphodiesterases in platelets", Thromb Haemost, 82, pp.412~423 (1999)
- Napeñas J, "Review of postoperative bleeding risk in dental patients on antiplatelet therapy", Oral Surg Oral Med Oral Pathol Oral Radiol, 115, pp.491~499 (2013)[DOI]
- Wangorsch G, "Time-resolved in silico modeling of finetuned cAMP signaling in platelets : feedback loops, titrated phosphorylations and pharmacological modulation", BMC Syst Biol, 5, pp.178~ (2011)[DOI]
- Barbara Coles, "Nitrolinoleate Inhibits Platelet Activation by Attenuating Calcium Mobilization and Inducing Phosphorylation of Vasodilator-stimulated Phosphoprotein through Elevation of cAMP", Journal of Biological Chemistry, 277(8), pp.5832~5840 (2002), American Society for Biochemistry & Molecular Biology (ASBMB)[DOI]
- Wentworth JK, "Vasodilator-stimulated phosphoprotein(VASP)is phosphorylated on Ser157 by protein kinase C-dependent and –independent mechanisms in thrombin-stimulated human platelets", Biochemical J, 393, pp.555~564 (2006)[DOI]
- Holmsen H, "The selectivity of the thrombininduced platelet release reaction : subcellular localization of released and retained constituents", J Lab Clin Med, 75, pp.840~855 (1970)
- Mustard JF, "Factors influencing platelet function : adhesion, release, and aggregation", Pharmacol Rev, 22, pp.97~187 (1970)